609 related articles for article (PubMed ID: 34968492)
1. Mechanisms of ketamine and its metabolites as antidepressants.
Hess EM; Riggs LM; Michaelides M; Gould TD
Biochem Pharmacol; 2022 Mar; 197():114892. PubMed ID: 34968492
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of ketamine action as an antidepressant.
Zanos P; Gould TD
Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
Hashimoto K
Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
[TBL] [Abstract][Full Text] [Related]
4. cAMP-dependent protein kinase signaling is required for (
Riggs LM; Pereira EFR; Thompson SM; Gould TD
J Neurophysiol; 2024 Jan; 131(1):64-74. PubMed ID: 38050689
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine.
Shaffer CL; Dutra JK; Tseng WC; Weber ML; Bogart LJ; Hales K; Pang J; Volfson D; Am Ende CW; Green ME; Buhl DL
Neuropharmacology; 2019 Jul; 153():73-81. PubMed ID: 31015046
[TBL] [Abstract][Full Text] [Related]
6. NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Zanos P; Moaddel R; Morris PJ; Georgiou P; Fischell J; Elmer GI; Alkondon M; Yuan P; Pribut HJ; Singh NS; Dossou KS; Fang Y; Huang XP; Mayo CL; Wainer IW; Albuquerque EX; Thompson SM; Thomas CJ; Zarate CA; Gould TD
Nature; 2016 May; 533(7604):481-6. PubMed ID: 27144355
[TBL] [Abstract][Full Text] [Related]
7. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
Zanos P; Highland JN; Liu X; Troppoli TA; Georgiou P; Lovett J; Morris PJ; Stewart BW; Thomas CJ; Thompson SM; Moaddel R; Gould TD
Br J Pharmacol; 2019 Jul; 176(14):2573-2592. PubMed ID: 30941749
[TBL] [Abstract][Full Text] [Related]
8. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2
Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS
Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant-relevant concentrations of the ketamine metabolite (2
Lumsden EW; Troppoli TA; Myers SJ; Zanos P; Aracava Y; Kehr J; Lovett J; Kim S; Wang FH; Schmidt S; Jenne CE; Yuan P; Morris PJ; Thomas CJ; Zarate CA; Moaddel R; Traynelis SF; Pereira EFR; Thompson SM; Albuquerque EX; Gould TD
Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5160-5169. PubMed ID: 30796190
[TBL] [Abstract][Full Text] [Related]
10. Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions.
Chou D
Neuropharmacology; 2020 Jun; 170():108068. PubMed ID: 32222405
[TBL] [Abstract][Full Text] [Related]
11. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.
Yao N; Skiteva O; Zhang X; Svenningsson P; Chergui K
Mol Psychiatry; 2018 Oct; 23(10):2066-2077. PubMed ID: 29158578
[TBL] [Abstract][Full Text] [Related]
12. (
Zanos P; Highland JN; Stewart BW; Georgiou P; Jenne CE; Lovett J; Morris PJ; Thomas CJ; Moaddel R; Zarate CA; Gould TD
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6441-6450. PubMed ID: 30867285
[TBL] [Abstract][Full Text] [Related]
13. Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model.
Zhang K; Toki H; Fujita Y; Ma M; Chang L; Qu Y; Harada S; Nemoto T; Mizuno-Yasuhira A; Yamaguchi JI; Chaki S; Hashimoto K
Psychopharmacology (Berl); 2018 Nov; 235(11):3177-3185. PubMed ID: 30215218
[TBL] [Abstract][Full Text] [Related]
14. Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.
Gould TD; Zarate CA; Thompson SM
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():213-236. PubMed ID: 30296896
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
[TBL] [Abstract][Full Text] [Related]
16. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
17. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.
Yang C; Yang J; Luo A; Hashimoto K
Transl Psychiatry; 2019 Nov; 9(1):280. PubMed ID: 31699965
[TBL] [Abstract][Full Text] [Related]
18. Ketamine and phencyclidine: the good, the bad and the unexpected.
Lodge D; Mercier MS
Br J Pharmacol; 2015 Sep; 172(17):4254-76. PubMed ID: 26075331
[TBL] [Abstract][Full Text] [Related]
19. NMDA antagonist treatment of depression.
Williams NR; Schatzberg AF
Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
[TBL] [Abstract][Full Text] [Related]
20. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
